Back to top

Curis (CRIS) Advances TakeAim CLL Study with Patient Enrollment Progress

Curis (CRIS) Advances TakeAim CLL Study with Patient Enrollment Progress

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Curis, Inc. (CRIS)